Stryker's Q2 Surge Tempers Near-Term Fears, But Rich Valuation Keeps Risk Elevated

What happened

Stryker reported 9% organic revenue growth and 17.9% adjusted EPS growth in Q2 2026, signaling a robust recovery from an earlier cybersecurity incident that had disrupted operations. The results underscore the company's durable competitive advantages in robotics, MedSurg, and neurovascular, with strong demand across segments despite lingering tariff and cost pressures. While the quarter reaffirms the growth story, the stock continues to trade at a rich ~46x earnings and ~30x EV/EBITDA, offering little margin of safety relative to a DCF-based intrinsic value near $124. Investors cheered the resilience, but the elevated multiple means that any subsequent stumble in growth, margin, or integration of large acquisitions could trigger sharp de-rating. Overall, Stryker remains a high-quality MedTech compounder, but the risk/reward remains skewed for those demanding a meaningful cushion against execution missteps.

Implication

The Q2 2026 beat, with 9% organic growth and 17.9% EPS expansion, demonstrates Stryker's ability to overcome operational disruptions and sustain above-market growth, supporting the bull case for its robotics and neurovascular franchises. However, the stock's premium multiple (~46x earnings) leaves no room for error, especially with ongoing tariff headwinds and integration risks from recent acquisitions like Inari Medical. The recovery from the cyber incident highlights operational resilience, but the rich valuation already prices in several years of flawless execution, making the margin of safety razor-thin. For existing holders, the report reinforces that the company's moat is intact, but profit-taking on strength remains prudent; for prospective buyers, waiting for a pullback toward a more reasonable multiple would offer a better risk/reward. Ultimately, Stryker remains a high-quality asset, but disciplined investors should remain on the sidelines until the valuation offers a more compelling entry.

Thesis delta

The robust Q2 recovery and strong adjusted EPS growth suggest the near-term operational risks from the cyber incident are contained and the growth trajectory is intact. While this does not eliminate the overvaluation concern, it reduces the immediate downside pressure, shifting the stance from POTENTIAL SELL to WAIT, as the premium multiple still limits upside.